Schonfeld Strategic Advisors LLC lessened its holdings in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 45.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 68,100 shares of the company's stock after selling 56,200 shares during the period. Schonfeld Strategic Advisors LLC owned about 0.29% of UroGen Pharma worth $725,000 at the end of the most recent quarter.
Several other hedge funds have also recently modified their holdings of the business. Nantahala Capital Management LLC bought a new position in UroGen Pharma in the fourth quarter worth approximately $14,608,000. Rosalind Advisors Inc. acquired a new position in shares of UroGen Pharma in the 4th quarter valued at $9,266,000. Price T Rowe Associates Inc. MD raised its stake in UroGen Pharma by 2,968.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 393,984 shares of the company's stock worth $4,197,000 after acquiring an additional 381,145 shares during the last quarter. Silverarc Capital Management LLC lifted its position in UroGen Pharma by 24.3% during the 4th quarter. Silverarc Capital Management LLC now owns 1,120,473 shares of the company's stock worth $11,933,000 after acquiring an additional 219,344 shares during the period. Finally, Alliancebernstein L.P. lifted its position in UroGen Pharma by 751.5% during the 4th quarter. Alliancebernstein L.P. now owns 199,259 shares of the company's stock worth $2,122,000 after acquiring an additional 175,859 shares during the period. Hedge funds and other institutional investors own 91.29% of the company's stock.
UroGen Pharma Stock Down 9.0%
NASDAQ:URGN traded down $1.00 during mid-day trading on Tuesday, hitting $10.14. The stock had a trading volume of 914,547 shares, compared to its average volume of 545,417. UroGen Pharma Ltd. has a twelve month low of $8.94 and a twelve month high of $20.70. The company has a market capitalization of $467.52 million, a PE ratio of -3.22 and a beta of 0.66. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The stock has a 50-day simple moving average of $10.66 and a two-hundred day simple moving average of $10.97.
UroGen Pharma (NASDAQ:URGN - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The business had revenue of $20.25 million for the quarter, compared to the consensus estimate of $22.71 million. On average, equities research analysts anticipate that UroGen Pharma Ltd. will post -3.12 EPS for the current year.
Analyst Ratings Changes
URGN has been the subject of a number of recent research reports. LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They set a "buy" rating and a $31.00 price target for the company. Scotiabank assumed coverage on UroGen Pharma in a research note on Wednesday, April 16th. They issued a "sector outperform" rating and a $23.00 target price on the stock. Guggenheim reiterated a "buy" rating on shares of UroGen Pharma in a research report on Tuesday, April 29th. HC Wainwright restated a "buy" rating and issued a $55.00 price objective on shares of UroGen Pharma in a research report on Tuesday. Finally, D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 price objective on shares of UroGen Pharma in a report on Thursday, May 8th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $32.86.
Read Our Latest Analysis on URGN
About UroGen Pharma
(
Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Further Reading
Before you consider UroGen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UroGen Pharma wasn't on the list.
While UroGen Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
